Here's everything you need to know about the Battlefield 6 free trial, including its start date, how to join, and more.

In December 2022, inside a lab the size of a football field in California, 192 lasers fired simultaneously at a tiny gold capsule. For a fraction of a second, humankind achieved what the stars have ...

Abstract: Cloud-free image reconstruction is of great significance for improving the quality of optical satellite images that are vulnerable to bad weather. When cloud cover makes it impossible to ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced ...

Go To The Website Using The Button Above. Follow The On-Screen Steps To Install And Activate Fusion 360 On Your Mac Device. With Fusion 360, users can create precise mechanical parts, design complex ...

TOKYO, Oct. 31, 2025 /PRNewswire/ -- Alpha Fusion Inc. (Headquarters: Chiyoda-ku, Tokyo; CEO: Sunao Fujioka; hereinafter "Alpha Fusion") today announced the initiation of a company-sponsored Phase I ...

– Aiming to establish af-001 as a new therapeutic option for radioactive iodine (RAI)-naive patients with differentiated thyroid cancer – TOKYO, Oct. 31, 2025 /PRNewswire/ -- Alpha Fusion Inc.

The Akston Biosciences Corporation partnered with Purdue University to develop a drug targeting PD-L1 in dogs with solid tumors. A new clinical study will evaluate a first–in–class immuno-enhancing ...

The Phase I study aims to evaluate BMF-650’s initial efficacy, tolerability and safety. Credit: angellodeco / Shutterstock.com. Biomea Fusion has dosed the first participant in the Phase I trial of ...

SAN CARLOS, Calif. - Biomea Fusion, Inc. (NASDAQ:BMEA), currently trading at $1.46 and identified as undervalued by InvestingPro analysis, announced Monday it has dosed the first patient in a Phase I ...

SAN CARLOS, Calif. - Biomea Fusion, Inc. (NASDAQ:BMEA), currently trading at $1.46 and identified as undervalued by InvestingPro analysis, announced Monday it has dosed the first patient in a Phase I ...